It has been supposed that anti-TNF-α treatment could cause an inhibition of bone turnover mediated by a reduction of RANKL which could already be shown in patients with rheumatoid arthritis and anti-TNF-α therapy [5]. This evidence concerns the gene TNF and rheumatoid arthritis.